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ABSTRACT
Dysregulation of the cell cycle and cyclin-dependent kinases (cdks) is a hallmark of 
cancer cells. Intervention with cdk function is currently evaluated as a therapeutic option 
in many cancer types including neuroblastoma (NB), a common solid tumor of childhood. 
Re-analyses of mRNA profiling data from primary NB revealed that high level mRNA 
expression of both cdk1 and its corresponding cyclin, CCNB1, were significantly associated 
with worse patient outcome independent of MYCN amplification, a strong indicator of 
adverse NB prognosis. Cdk1 as well as CCNB1 expression were readily detectable in all 
embryonal tumor cell lines investigated. Pharmacological inhibition or siRNA-mediated 
knockdown of cdk1/CCNB1 induced proliferation arrest independent of MYCN status in NB 
cells. Sensitivity to cdk1 inhibition was modulated by TP53, which was demonstrated using 
isogenic cells with wild-type TP53 expressing either dominant-negative p53 or a short 
hairpin RNA directed against TP53. Apoptosis induced by cdk1 inhibition was dependent 
on caspase activation and was concomitant with upregulation of transcriptional targets 
of TP53. Our results confirm an essential role for the cdk1/CCNB1 complex in tumor cell 
survival. As relapsing embryonal tumors often present with p53 pathway alterations, 
these findings have potential implications for therapy approaches targeting cdks.
INTRODUCTION
Targeting the machinery that regulates the aberrant cell 
cycle associated with malignant tumor growth is currently 
regarded as a promising anti-cancer strategy. Genetic alt-
erations in cell cycle control genes have frequently been 
identified in childhood tumors first, with Rb1 as one of 
the most prominent examples [1, 2]. Among embryonal 
tumors, neuroblastoma (NB) is a prototypic malignancy 
with marked heterogeneity of clinical courses ranging 
from very aggressive behavior and poor patient outcome to 
spontaneous regression even without treatment [3]. Intensity 
of NB therapy depends on clinical characteristics such as age 
at diagnosis and metastatic spread of the disease, but also 
on molecular factors, most prominently the amplification 
status of the MYCN oncogene (reviewed in [4]). MYCN 
amplification/ mutation is the most frequent genetic aberration 
in NB affecting a single gene, which has been confirmed by 
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genome-wide mutational analyses [5]. Enhanced MYCN 
gene dosage is associated with early disease relapse and 
unfavorable prognosis. Several lines of evidence have also 
pointed to an intricate link of MYCN with proteins of the 
cell cycle machinery, resulting in synthetic lethality of CDK 
inhibition in MYC(N)-dependent cancers [6, 7]. It thus was 
hypothesized that interfering with MYCN functions will offer 
a route to tackle the most aggressive forms on NB and other 
MYCN-dependent cancers. As MYCN is a transcription 
factor with a wide range of target proteins and functions, 
it has been enigmatic for decades, which strategy would 
be optimal to interfere with MYC(N) functions. Recently, 
inhibition of Brd proteins, most notably Brd4, has been 
shown to be effectively down-regulating MYCN functions 
at least in preclinical models of embryonal tumors including 
medulloblastoma and neuroblastoma [8, 9]. Still, the clinical 
usefulness of these strategies has yet to be proven.
Here, we re-analyzed mRNA array profiling 
data obtained for > 100 primary NB to search for cell-
cycle regulated genes correlating with patient outcome 
and MYCN status. Among these candidate genes, we 
identified the cell cycle regulators Cyclin B1 (CCNB1) 
and the cell cycle dependent kinase 1 (cdk1) as intricately 
linked to patient’s prognosis. It is well known that cdk1 
is overexpressed in a variety of tumor entities including 
prostate cancer and oral squamous cell carcinoma [10, 
11]. Mechanistically, high levels of cdk1 promote tumor 
growth by stabilizing HIF1α [12] and contribute to 
neoplastic transformation by phosphorylation of YAP [13]. 
Selective inhibition of cdk1 function by small molecules 
such as RO-3306 is feasible [14] and cdk1 inhibition had 
synergistic effects in combination with PARP inhibition 
in preclinical models of breast cancer [15]. In the study 
presented here, we investigated the effects of CCNB1/cdk1 
knock down by siRNA and analyzed the consequences 
of RO-3306 mediated cdk1 inhibition as a function of 
variable expression of MYCN and p53 in preclinical 
models of embryonal tumors including neuroblastoma, 
medulloblastoma and rhabdomyosarcoma.
MATERIALS AND METHODS
Expression profiling of primary human NB
Affymetrix HuEx1.0 exon array data (GEO acc. 
No GSE32664) were re-analyzed for the purpose this 
study. The 101 NB samples used were from tumor banks 
in Essen and Ghent [16]. Treatment protocols and patient 
selection have been previously described [17]. In brief, 
we ensured a representative distribution of tumor stages 
(stage 1: n = 23; stage 2: n = 7; stage 3: n = 11; stage 4: 
n = 42; stage 4s: n = 18), with 75% of the patients 
(n = 76) older than one year at the time of diagnosis. 
The mean age at diagnosis was 607 days and MYCN 
amplification occurred in 19 patients. Microarray 
data were analyzed using the web-based frontend R2 
(r2.amc.nl).
Cell lines
Human neuroblastoma cell lines with high MYCN 
levels (IMR32, NGP, NLF, WAC2) or low MYCN 
levels (NB69, SHEP, SK-N-FI) were used. RH-41 
was established from a xenografted lung metastasis of 
alveolar rhabodomyosarcoma [18]. WAC2 is a subclone 
of SHEP cells engineered for stable overexpression 
of MYCN [19]. Inducible MYCN activation was 
achieved using SHEP MYCN-ER cells. Briefly, nuclear 
translocation and activation of MYCN in SHEP MYCN-
ER cells expressing a fusion protein of MYCN and the 
estrogen-responsive domain of the estrogen receptor 
was induced by addition of 200 nM 4-OHT for indicated 
time points as described [20]. Down-regulation of 
p53 in wt-TP53 NB cell lines IMR32 and NGP was 
facilitated by an shRNA directed against human p53, 
while a shRNA directed against murine p53 served 
as negative control [21]. HD-MB3 medulloblastoma 
cells expressing a dominant-negative variant of p53 
(HD-MB3 p53-dn) cells were generated by transfecting 
HD-MB3 with pMSCV-puro-p53DD, and selected for 
stable transfectants with 2 μg puromycin/ ml medium 
[8]. MYCN was down-regulated in a MYCN-amplified 
cell line, IMR5, by using a tet-inducible two vector 
system [22]. In these cells, designated IMR5-shMYCN, 
addition of tetracycline (1 μg/ml) to the culture media 
induced ectopic overexpression of an shRNA directed 
against NMYC [22]. All cell lines were cultivated 
in RPMI 1640 containing 10% FCS and antibiotics 
as previously described [23]. Identity of tumor cell 
lines was confirmed by STR genotyping. The human 
fibroblast cell line NHDF served as non-tumorigenic 
control.
Gene knockdown using small interfering RNAs 
(siRNAs)
Cells were transfected with 50 nM siRNA 
directed against either CCNB1 or cdk1 (Qiagen, 
Hilden, Germany) using HiPerFect transfection reagent 
(Qiagen). As a control, the cells were transfected with 
a non-targeting siRNA (D-001210-01-05, Thermo 
Scientific Dharmacon, Waltham, MA). Down-regulation 
of target mRNA was validated by semi-quantitative real-
time PCR.
Cell cycle analysis
Cells were cultivated in the presence of the cdk1-
inhibitor, RO-3306, for 24 h or 48 h, harvested, and 
stained with propidium iodide as described in [24]. The 
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DNA content as a function of the cell cycle phase was 
analyzed using a FC500 Flow Cytometer (Beckman 
Coulter).
Cell viability assays
Cells were seeded in triplicates into 96 well plates to 
adhere. After 24 hours the cells were treated with either a 
cdk inhibitor, RO-3306, or siRNA for 48 h. Cell viability 
was determined by a MTT (3-(4, 5-dimethylthiazol-2-
yl)-2, 5-diphenyltetrazoliumbromide) assay.
Western blot
Cells were washed with cold PBS and lysed in 
RIPA buffer containing proteases and phosphatase 
inhibitors (Roche, Penzberg, Germany). Gel 
electrophoresis, transfer to nitrocellulose membranes, 
blotting and visualization was performed as described 
[25]. The membranes were probed with the following 
antibodies and dilutions: p53 (1:500; Santa Cruz), p21 
(1:1000; Cell Signaling), CCNB1 (1:500; Abnova), cdk-1 
(1:500; Milipore), NMYC (1:500: Cell Signaling), pRb-
Ser807/811 (1:2000; Cell Signaling), PP1α and pPP1α-
Thr320 (1:500; Cell Signaling).
Real-time PCR and semiquantitative PCR
RNA was isolated from cells using the High Pure 
RNA isolation Kit (Roche). The cDNA was synthesized 
with the Transcription First Strand cDNA Synthesis Kit 
(Roche). For semiquantitative PCRs 100 ng cDNA was 
used and GAPDH was co-amplified as a control. Real-time 
PCRs was performed using predesigned primers (Qiagen) 
and monitored using SYBR green fluorescence on a 
StepOnePlus Real-Time PCR system (Life Technologies). 
Target gene expression was calculated using the delta Ct 
method using GAPDH as internal control.
Apoptosis and caspase assays
Apoptosis was monitored following cdk inhibition 
for 48 h using the Cell Death Kit Plus (Roche) allowing for 
the specific determination of mono- and oligonucleosomes 
as consequence of DNA fragmentation. Caspase activity 
was determined using luminogenic Caspase 8 or Caspase 
9 substrates (Caspase Glo Assay, Promega), respectively, 
according to the manufacturer’s instructions. For rescue 
experiments, cells were seeded on 12 well plates for 24 h 
and then treated with either RO-3306 in the presence 
or absence of the pan-caspase inhibitor, Q-VD-OPh 
(Calbiochem), for 48 h.
Statistical analyses
Statistical significance of differences between 
treatment groups was determined using a Student t-test 
implemented in GradhPad Prism® 5.0 (GraphPad Software, 
San Diego, CA), which was also used for graphical 
representation and calculation of standard deviation.
RESULTS
Cdk1 and CCNB1 mRNA expression are 
correlated with poor outcome independent of 
MYCN amplification in neuroblastoma
Data obtained from mRNA profiling of 101 primary 
neuroblastoma were re-analyzed for correlation of cell 
cycle genes with outcome and the MYCN amplification 
status. High expression of cdk1 or CCNB1 was linked 
to significantly worse outcome in the entire cohort 
(Figure 1A), and this was independent of the MYCN 
status (Figure 1B). Nevertheless, both cdk1 expression and 
CCNB1 expression were significantly higher in MYCN-
amplified tumor (Figure 1C). Additionally, survival 
probabilities were significantly lower in tumor with high 
expression of cdk2 (p = 0.006), cdk4 (p = 0.003) or cdk6 
(p = 0.045, Supplementary Figure S1A). Of these genes, 
only cdk4 was significantly associated with MYCN 
amplification status (p = 0.0002, Supplementary Figure 
S1B). As previously reported, upregulation of cdks is 
common in aggressive neuroblastoma [7, 26], but only 
CCNB1/cdk1 were predictive of outcome both in the 
entire cohort as well as in the MYCN normal group when 
the Cyclin/ cdk pairs were considered.
Cdk1 and CCNB1 are highly expressed in 
neuroblastoma cell lines
Expression of both cell cycle regulators, cdk1 
and CCNB1, were analyzed on mRNA and protein 
level in a panel of NB cell lines presenting either with 
low MYCN levels (NB69, SK-N-FI, SHEP) or with 
MYCN amplification/overexpression (IMR-32, NGP, 
NLF, WAC2). Both mRNA and protein levels of cdk1 
and CCNB1 were elevated in all NB cell lines and the 
human rhabdomyosarcoma cell line, RH-41, when 
compared to a human fibroblast cell line (NHDF, 
Figure 2). No significant correlation between the MYCN 
status and Cdk1/CCNB1 expression could be detected 
(Supplementary Figure S2). Of note, in SHEP cells 
engineered to activate MYCN upon addition of 4-OHT 
(SHEP MYCN-ER), CCNB1 mRNA (Figure 2A) but not 
protein levels (Figure 2B) were elevated compared to 
controls. Induction of shRNA-mediated down-regulation 
of MYCN in a MYCN-amplified cell line, IMR5, 
resulted in concomitant down-regulation of both Cdk1 
and CCNB1 (Supplementary Figure S3). Thus, MYCN is 
a sufficient but not necessary regulator of CCNB1/cdk1 
expression, and upregulaton of CCNB1 and cdk1 is a 
common feature of neuroblastoma cell lines irrespective 
of their MYCN status.
Oncotarget15428www.impactjournals.com/oncotarget
Knock-down of CCNB1 or cdk1 by specific 
siRNAs causes a decrease in NB cell proliferation
Transient downregulation of CCNB1 or cdk1 was 
achieved by sequence-specific siRNAs in a panel of five 
neuroblastoma cell lines. Both mRNA and protein levels 
of CCNB1 and cdk1 were significantly and specifically 
decreased 48 h after transfection (Figure 3A–3C). Cell 
viability after knock-down of CCNB1 was significantly 
reduced in SHEP and WAC2 cells, while reduction of cell 
viability upon knock-down of cdk1 (Figure 3D) was only 
significant in NB69 cells. A trend for reduced viability was 
present in all other cell lines, with the exception of the 
p53-mutated cell line, SK-N-FI, in which cdk1 or CCNB1 
downregulation had no effect (Figure 3D).
The cdk1 inhibitor, RO-3306, causes a 
significant reduction of cell viability in 
neuroblastoma cell lines
To further characterize the impact of the cdk1/
CCNB1 axis on NB cell survival, we used a previously 
described cdk1 inhibitor, RO-3306 [14]. The effect of RO-
3306 on cell viability was analyzed in the same cell line 
panel as described above. Additionally, a human fibroblast 
cell line (NHDF) as well as a rhabdomyosarcoma cell line, 
RH-41, were included for evaluation of tumor cell specific 
effects. All cell lines responded to RO-3306 treatment 
by decreased cell viability in a concentration dependent 
manner (Figure 4A, Table 1). Interestingly, both the 
rhabdomyosarcoma cells as well as the non-tumorigenic 
NHDF cells were more resistant to RO-3306 than the NB 
cells in our panel. IC50-values in NB cells ranged between 
1.3 μM and 4 μM, while RH-41 cells had an IC50-value > 
8 μM. In isogenic NB cells with low (SHEP) or high levels 
of MYCN (WAC2) response to RO-3306 was comparable 
(IC50
48 h
:1.3 μM and 1.8 μM, respectively).
Sensitivity to cell cycle inhibition is modulated 
by p53 status but not by MYCN levels
Interestingly, all cell lines harboring a p53 
mutation, SK-N-FI, NLF and RH-41, displayed decreased 
sensitivity towards treatment with RO-3306 compared to 
p53 wt cells (data are summarized in Table 1). Neither 
down-regulation of MYCN in IMR5-TR-shNMYC 
cells (Supplementary Figure S3) nor induction of 
MYCN activity in SHEP MYCN-ER cells significantly 
altered cell viability (Supplementary Figure S4). Thus, 
the MYCN status did not affect sensitivity to RO-
3306. The same p53-dependent effect was observed, 
when a pan cdk-inhibitor (JNJ-7706621) was used 
(Table 1 and Supplementary Figure S3–S5). Again, 
sensitivity to JNJ-7706621 did not depend on MYCN 
(Supplementary Figure S3C). Furthermore, when all cell 
lines were grouped according to their p53 status, cell 
Figure 1: CCNB1 and cdk1 mRNA expression correlate with a poor outcome and MYCN expression in neuroblastoma.  
A, B. Kaplan Meyer analyses of 101 primary NB revealed a significant correlation between overall survival and both cdk1 and CCNB1 mRNA 
expression. The cohort was split into two groups with either “high” or “low” cdk1 / CCNB1 expression and the numbers depict the respective 
group size, when the entire cohort (A) or the subset with normal MYCN status (B) were analyzed. P-values were adjusted for multiple testing 
of different group sizes using a Bonferroni correction implemented in the R2 visualisation module (accessible at http://r2.amc.nl). C. Tumors 
harboring a MYCN amplification have significantly higher cdk1/CCNB1 expression compared to MYCN non-amplified tumors.
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Figure 2: Cdk1 and CCNB1 are highly expressed in neuroblastoma cell lines. A. CCNB1 and cdk1 mRNA-levels were 
analyzed by semi-quantitative PCR in seven neuroblastoma cell lines (IMR32, NGP, NLF, WAC2, SHEP, NB69, SK-N-FI) and in the 
rhabdomyosarcoma cell line RH-41. Expression was normalized to IMR32 cells and compared to the human fibroblast cell line (NHDF). 
Cell lines were grouped according to their MYCN expression status (yellow= MYCN high, green= MYCN low). In SHEP-MYCN cells, 
MYCN can be targeted to the nucleus and thus activated by addition of 4-OHT (marked in red). B. Western Blot analyses revealed higher 
protein levels of cdk1 and CCNB1 in the tumor cell lines compared to NHDF cells. MYCN activation by 4-OHT in SHEP-MYCN cells did 
not result in elevated CCNB1 or cdk1 expression, although CCNB1 mRNA expression was higher compared to controls.
Figure 3: siRNA mediated knock-down of cdk1 and CCNB1 causes a reduction of cell viability. A–C. Transfection with 
siRNA against cdk1 (siCDK1) and CCNB1 (siCCNB1a, siCCNB1b) specifically downregulated the protein evels of the respective targets 
as revealed by Western Blot analyses. In (B) and (C), semi-quantitative real-time PCR for CDK1 and CCNB1 confirmed that down-
regulation of the respective mRNAs was also specific when compared to the controls. Values are presented as normalised to untreated control  
(“untr. ctrl.”). “transfection control” contained the transfection reagents only, while in “scrambled siRNA” an unrelated siRNA was used. 
D. Cell viabilty was measured by MTT assays after 48 h following siRNA transfection. Significant differences between transfection control 
and knockdown cells are shown in the diagram as follows ***: p < 0.001; **: p = 0.001–0.01; *: p = 0.01–0.05
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lines without functional p53 displayed 1.7-fold higher 
resistance to RO-3306 and 1.8-fold higher resistance to 
JNJ-7706621 (Supplementary Table 1). Specificity of 
cdk1 inhibition by RO-3306 in NB cells was analyzed 
by interrogating the phosphorylation status of the cdk1 
target protein phosphatase 1α (PP1α -Thr320) as well as 
phosphorylation of pRb at Ser 807/811, which is mainly 
governed by cdk4. In all cell lines except for p53-mutated 
SK-N-FI cells, a reduction of phosphorylated PP1α was 
observed after four hours following treatment with RO-
3306, while RO-3306 did not affect pRb-phosphorylation 
(Supplementary Figure S6). Thus, NB cell viability 
can be significantly reduced by cdk-1 inhibition, while 
sensitivity to RO-3306 and JNJ-7706621 correlated with 
p53-mutational status rather than with MYCN levels.
Sensitivity of NB cells to cdk1-inhibition is 
modulated by p53
To further analyse the impact of the p53 mutational 
status on NB cell response to RO-3306, we made use of 
previously described isogenic IMR32 and NGP cells, in 
which p53 knock-down is mediated by shRNA [21]. These 
cells were designated IMR32-LV-h-p53 and NGP-LV-
h-p53, respectively, and the results compared to parental 
cells or negative controls, which were stably transfected 
with shRNA against murine p53. Both cell lines also differ 
in the MDM2 status, as NGP cells harbor an amplification 
of MDM2, a negative regulator of p53. First, we excluded 
that knock-down of murine or human p53 had an effect on 
cdk1 or CCNB1 expression (Supplementary Figure S7). 
Interestingly, both p53 knock-down cell lines were more 
resistant to RO-3306 treatment when compared to the 
control cell lines and the parental cells. The fraction of 
viable IMR32-LV-h-p53 cells was also significantly higher 
at the highest concentration of RO-3306 tested (8 μM, 
Figure 5A), while NGP-LV-h-p53 were significantly more 
resistant than control cells at lower doses (Supplementary 
Figure S8A). To further delineate if p53 function was 
involved in RO-3306 mediated reduction of cell viability, 
we analyzed HD-MB3 medulloblastoma cells with or 
without expression of a dominant-negative form of p53 
Figure 4: Inhibition of cdk1 by a small molecule inhibitor, RO-3306, induces apoptosis and causes an activation of the 
p53 signaling pathway. A. Inhibition of cdk1 by RO-3306 caused decreased cell viability after 48 h in all NB cell lines investigated and 
also in the rhabdomyosarcoma cell line RH-41 in a concentration dependent manner. The human fibroblast cell line, NHDF, and the cell 
lines harboring p53 mutation (SK-N-FI, RH-41) were more resistant to RO-3306 than the tumor cell lines with p53 wild type. B. Cell cycle 
distribution was analyzed 24 h and 48 h after RO-3306 treatment. Only cells harboring a p53 mutation (SK-N-FI, NLF) presented with 
significantly higher fraction of G2 phase (left side), while all cell lines had significantly elevated subG1 indicative of apoptosis. C. Significant 
induction of apoptosis by RO-3306 could be confirmed in all cell lines by a colorimetric assay detecting nucleosomes. D. Activation of the 
p53 pathway in p53 wt cells shown by increased p53 and p21 protein levels. Significant differences between untreated cells and inhibitor 
treated cells are depicted in the entire diagram using the following code “***”: p < 0.001; “**”: p = 0.001–0.01; “*”: p = 0.01–0.05.
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(HDMB3 p53-dn, [27]). Here, lack of functional p53 
resulted in a twofold increased resistance to RO-3306 
(IC50: 3.9 μM) compared to the parental cell line (IC50: 
1.8 μM, Figure 5A). Taken together, cells with normal 
p53 status were more sensitive to RO-3306 treatment 
compared to their isogenic counterparts with either 
reduced levels or impaired function of p53.
RO-3306 induces cell death and a p53 status 
dependent increase in G2 phase cells
As cdk1 is a cell cycle regulator promoting the 
transition from G2- to M-phase, we next investigated 
the effects of cdk1 inhibition on cell cycle distribution 
and apoptosis. Cell cycle analyses revealed an increase 
of the subG1-phase in our NB cell line panel 24 h and 
48 h after RO-3306 treatment. This effect was significant 
in all cell lines independent of p53 mutational status 
(Figure 4B). Enhanced apoptosis could also be confirmed 
by an assay detecting isolated nucleosomes (Figure 4C). 
In p53-wt cells, activation of the p53-pathway by RO-
3306 resulted in enhanced p21 expression after 24 hours, 
while p53-mutated cells failed to activate p21 (Figure 4D, 
Supplementary Figure S9). Additionally, the p53 
downstream targets BAX and MDM2 were upregulated 
after cdk1 inhibition in p53 wt cells (Supplementary 
Figure S9). Instead, p53 mutated cell lines (SK-N-FI 
and NLF) presented with a significant increased fraction 
of cells in G2-phase. Similar results were also obtained 
in the model systems with reduced p53 levels (IMR32-
LV-h-p53) and in cells expressing a dominant negative 
variant of p53 (HDMB3 p53-dn, Figure 5). Next, we 
assessed, if the observed G2 arrest induced by RO-3306 
was dose-dependent. Treatment of parental IMR32 and 
HDMB3 cells with higher concentrations of RO-3306 did 
not increase the number of G2-phase cells after 48 hours 
(Figure 5B), while both the parental, MDM2-amplified, 
NGP cells as well as NGP-LV-h-p53 cells presented 
with a G2-phase arrest 24 h and 48 h (Supplementary 
Figure S8B). Thus, cell cycle analyses revealed that 
p53-deficiency modulates response to cdk1 inhibition by 
increasing the fraction of cells in G2, but that decreased 
p53-function does not impair RO-3306-induced apoptosis.
RO-3306-induced apoptosis is caspase dependent
As treatment with RO-3306 resulted in an increased 
fraction of apoptotic cells independent of their p53 status, 
we next addressed involvement of the extrinsic and the 
intrinsic apoptotic pathway by monitoring caspase 8 
and caspase 9 activity, respectively. Activation of both 
caspase 8 and caspase 9 upon treatment with RO-3306 
was highest in the p53 mutated NB cell lines SK-N-FI and 
NLF (Figure 6A). This effect was confirmed by a rescue 
Table 1: Molecular characteristics of cell lines used in this study. Displayed are the p53 status, the MYCN 
status of cells and subclones and their sensitivity to RO-3306, a cdk1-inhibitor and to a pan cdk inhibitor, JNJ-7706621, 
used throughout this study. In the column “p53 status” “knock-down” depicts cell lines with expression of a shRNA directed 
against p53, while “dominant neg. form” refer to HDMB-3 cells expressing a dominant negative variant of p53. In the column 
“MYCN status”, cells are divided into the categories “amplified” or “non-amplified” with the exception of WAC2, which is a 
stably MYCN-overexpressing subclone of SHEP.
Cell line IC50 RO3306 IC50 JNJ-7706621 p53 status MYCN status
WAC2 1.80 µM 0,6 µM wt high
SHEP 1.30 µM 1 µM wt single-copy
NB69 2.30 µM 2,3 µM wt single-copy
SK-N-FI 4.00 µM 4,1 µM mut. single-copy
NLF 3.80 µM 3,4 µM mut. ampl.
RH-41 > 8.0 µM 2,8 µM mut. single-copy
IMR-32 1.6 µM 1,3 µM wt ampl.
IMR-32 LV-m-p53 1.6 µM 1,3 µM wt ampl.
IMR-32 LV-h-p53 2.4 µM 2,1 µM knock-down ampl.
NGP 4.0 µM 3,1 µM wt ampl.
NGP LV-m-p53 4.0 µM 3,1 µM wt ampl.
NGP LV-h-p53 6.0 µM 3,1 µM knock-down ampl.
HDMB-3 1.8 µM 1,6 µM wt ampl.
HDMB-3 p53-dn 3.9 µM 6 µM dominant neg. form ampl.
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experiment, when co-administration of RO-3306 and a 
pan-caspase inhibitor, Q-VD-OPh, resulted in a significant 
reduction of the apoptotic response in all cell lines 
independent of the p53 status (Figure 6B, Supplementary 
Figure S10A). Only in NB69 cells, co-administration 
of RO-3306 and Q-VD-OPh resulted in a significant 
increase of cells in G2-phase in addition to suppression of 
apoptosis (Supplementary Figure S10B). Hence, canonical 
caspase-mediated apoptosis seems to be responsible for 
the observed cell death upon RO-3306 treatment.
Figure 5: Sensitivity to RO-3306 is modulated by p53 functional status. A. HDMB-3 medulloblastoma cells expressing a 
dominant negative p53 variant (HDMB-3 p53-dn) are more resistant to RO-3306 treatment than the parental HDMB-3 cells (upper part). 
Additionally, IMR32-NB cells harboring a shRNA against human p53 (IMR32-LV-h-p53) were less sensitive to RO-3306 compared to 
control cells transfected with shRNA directed against murine p53 (IMR32-LV-h-p53) and parental IMR-32 cells. B. Cell cycle analyses 
performed for the same cell panel as in (A) revealed a significant increase in G2 phase 48 hours after RO-3306 treatment only in the 
absence of functional p53. When control cells were treated at higher doses corresponding to the IC50 values of cells without functional p53 
(indicated by an orange line), IMR-32 cells had also a significantly increased G2 fraction 48 hours after treatment with RO-3306. Again, in 
all cell lines RO-3306 caused an increase in the sub G1 fraction. Significant differences between untreated cells and inhibitor treated cells 
are depicted using the following code “***”: p < 0.001; “**”: p = 0.001–0.01; “*”: p = 0.01–0.05.
Figure 6: RO-3306 induced apoptosis is mediated by caspases. A. Caspase-8 and -9 activities were investigated by colorimetric 
assays (“Caspase Glo”, Promega). RO-3306 caused elevated caspase-8 and -9 activities in all cell lines investigated after 48 hours and 
this increase was significant as indicated. B. RO-3306-induced apoptosis could be abrogated by co-treatment with a pan-caspase inhibitor, 
(Q-VD-OPh, used at a final concentration of 12.5 μM). This rescue effect was observed using a colorimetric assay (Cell Death ELISA, 
Roche) and confirmed by FACS-based cell cycle analyses (Supplementary Figure S10). Significances between RO-3306-treated cells and 
untreated cells (A) or between RO-3306 treated cells in the presence of absence of pan-caspase inhibitor are depicted using the following 
code: “***”: p < 0.001; “**”: p = 0.001–0.01; “*”: p = 0.01–0.05.
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DISCUSSION
Uncontrolled proliferation plays a major role in 
cancer development and progression [28]. Under normal 
physiological conditions, cell cycle control is executed by 
a delicate interplay of cyclin dependent kinases (cdks) and 
their corresponding cyclins, whereas overexpression or 
amplification of cyclins and cdks is observed in various 
cancer types. Therefore, several cdk inhibitors were 
developed and entered early clinical phases, but those 
investigational drugs, including the pan cdk inhibitors 
flavopiridol and roscovitine, showed moderate effects and 
dose-limiting toxicities. Finding a therapeutic window was 
reported as a major difficulty [29]. In recent years, more 
specific inhibitors became available, which might have 
preferable anti-tumor characteristics compared to the broad 
spectrum inhibitors used before. Of note, a combined cdk4/
cdk6 inhibitor, palbociclib, recently received “breakthrough 
therapy” status for the treatment of ER+/HER2- breast 
cancer. However, identification of the best suited inhibitor 
will depend on the tumor type and still is a challenge.
In neuroblastoma (NB), genomic amplifications of 
CCND1 [30] and cdk4 [31] were observed in primary 
tumors, albeit at low frequency. Nevertheless, cdk4 and 
CCND1 levels are found to be generally expressed at 
higher levels in NB than in other tumors [30]. Inhibition 
of cdk4 and cdk6 has also been shown promising activity 
in preclinical NB models [32]. Moreover, inactivation 
of cdk2 is synthetic lethal in MYCN-amplified tumor 
cells and cdk2 was also proposed as a potential target for 
NB therapy [7, 33]. Here, we confirm high expression 
of cdks as a feature of NB with unfavorable prognosis 
and additionally identify CCNB1/cdk1 expression as an 
MYCN-independent risk factor (Supplementary Figure 
S1). Both CCNB1 and cdk1 mRNAs are highly expressed 
in primary NB and this was correlated with reduced overall 
survival (Figure 1). NB cell lines derived from high-stage, 
aggressive tumors as well as the rhabdomyosarcoma 
cell line RH-41 all presented with high cdk1/CCNB1 
expression independent of the MYCN amplification status 
(Figure 2). Induction of MYCN in a MYCN-normal cell 
line caused upregulation of cdk1/CCNB1 expression, 
while decreased MYCN expression in a MYCN-amplified 
cell line resulted in reduced cdk1/CCNB1 expression 
(Supplementary Figure S3B). However, the high 
expression levels of cdk1/CCNB1 in cell lines with normal 
MYCN (Figure 2), which are also found in primary tumors 
in the absence of MYCN amplification, left us to conclude 
that MYCN is a sufficient but not a necessary driver of 
cdk1/CCNB1 in neuroblastoma cells.
A prominent downstream target of the CCNB1/
cdk1 complex is the tumor suppressor p53, which restricts 
uncontrolled cell growth by inducing cell cycle arrest, 
mainly in G1, or apoptosis. Inhibition of CCNB1/cdk1 
reactivated and stabilized p53 in cells with functional loss 
of p53 [34]. Using sequence-specific siRNAs (Figure 3) 
or the quinolinyl thiazolinone derivative, RO-3306 ( [14], 
Figure 4), to inhibit CCNB1/cdk1, we observed decreased 
cell viability and an increased number of apoptotic cells 
in all NB cell lines investigated. Interestingly, inhibitor 
efficiency depended on the p53 status, as cells with p53 
mutation were more resistant to treatment with RO-
3306. The impact of the p53 status on inhibitor efficiency 
could be confirmed in p53 knock down cells (Figure 5A). 
Additionally, higher inhibitor concentrations were 
required to decrease viability in a cell line (NGP) with 
functional inactivation of p53 due to MDM2 amplification. 
Increased resistance to cdk inhibition in the absence of 
functional p53 was not confined to neuroblastoma cells 
as shown in HDMB3 medulloblastoma cells expressing a 
dominant negative variant of p53 (Figure 5A). In all cell 
lines analyzed, p53 status did not affect CCNB1 or cdk1 
expression mRNA level or protein levels. Thus, sensitivity 
to CCNB1 or cdk1 inhibition was modulated by functional 
p53, but was not dependent on the MYCN status.
The most prominent function of CCNB1 and cdk1 
is to form a complex activating the serine/threonine kinase 
function of cdk1 thus regulating the transition from G2-
phase to M-phase. As cdk1 is also sufficient to drive the 
entire cell cycle [35], we checked for specific changes 
in cell cycle distribution upon cdk1 inhibition. In cells 
with intact p53 signaling, apoptosis was the predominant 
response to cdk1 inhibition (Figure 4C). Our results add 
further evidence to the hypothesis that p53 status rather than 
MYCN expression governs the sensitivity to cdk inhibition 
(Supplementary Figure S3–5) and, moreover, indicate that 
the cdk1/CCNB1 axis is important for the resistance to cdk 
inhibition by loss of functional p53 in neuroblastoma cells 
(Supplementary Table 1). Accumulation of p53 protein after 
cdk1 inhibition coincided with transcriptional upregulation 
of p53 targets, p21, BAX and MDM2 (Supplementary 
Figure S9). These results confirm earlier reports obtained 
upon RO-3306 treatment of AML cells [36]. It is also 
known that p53 can be phosphorylated by cdk1 at Ser315 
and that this phosphorylation destabilizes p53 (ref. [34]). 
Therefore, earlier reports that cdk1 inhibition might 
function independently of the cellular p53 status, could 
possibly be attributed to unspecific inhibitors used [37]. In 
cells without functional p53 a significant increase in G2 
phase was the major response to RO-3306 (Figure 4B, 
5B), and this could be confirmed in cells expressing either 
a shRNA targeting p53 or a dominant negative form of p53. 
Mechanistically, this difference in the apoptotic response 
could not be attributed to differential activation of effector 
caspases, as caspase 8 and 9 were activated after 48 h. 
Caspase-9 phosphorylation by cdk1 has been described 
to protect cells from apoptosis during mitosis [38], while 
caspase-8 cleavage and thus activation is regulated by 
concerted action of cdk1 and polo-like kinase 1 (Plk1, ref. 
[39]). Consequently, a pan-caspase inhibitor could block 
activation of both caspase-8 and caspase-9 activation 
observed upon RO-3306 treatment and could significantly 
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rescue cells from RO-3306-induced apoptosis independent 
of the p53 status (Figure 6). Thus, by a combination of loss-
of-function and rescue experiments we could confirm p53 
as well as caspase-8 and caspase-9 as important modulators 
of the response to cdk1-inhibition by RO-3306.
In summary, we here demonstrate that cdk1 
inhibition by RO-3306 causes apoptosis in a panel of 
preclinical embryonal tumor models with wild-type 
53 and that inhibitor efficiency was determined by p53 
mutational status. Induction of apoptosis by cdk1-
inhibition depended on functional p53 signaling, while 
in cells with p53 inactivation or in cells harboring TP53 
mutations a significant G2 phase arrest was observed. 
Further investigation of these effects in in vivo models is 
warranted to evaluate the efficacy of targeting cdk1 as a 
novel tool in tumor therapy.
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